Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer

Article

There are many clinical trial opportunities, Tolaney says, before surgery.

Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.

“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.

Related Videos
Image of a woman with brown shoulder-length hair in front of a gray background that says CURE.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content